The estimated Net Worth of Gianfranco Nazzi is at least $4.71 Million dollars as of 3 March 2021. Mr. Nazzi owns over 1,400 units of Teva- Pharmaceutical Industries stock worth over $25,144 and over the last 7 years he sold TEVA stock worth over $1,233,680. In addition, he makes $3,449,170 as Executive Vice President - International Markets Commercial at Teva- Pharmaceutical Industries.
Gianfranco has made over 8 trades of the Teva- Pharmaceutical Industries stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 12,935 units of TEVA stock worth $136,852 on 4 March 2021.
The largest trade he's ever made was selling 75,587 units of Teva- Pharmaceutical Industries stock on 28 February 2021 worth over $821,631. On average, Gianfranco trades about 7,134 units every 30 days since 2018. As of 3 March 2021 he still owns at least 1,400 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Mr. Nazzi stock trades at the bottom of the page.
Gianfranco Nazzi serves as Executive Vice President - International Markets Commercial of the Company. He served as President and CEO of International Markets, Global Generic Medicines Group. Mr. Nazzi joined Teva as Senior Vice President, Specialty Medicines Europe in 2014. Prior to joining Teva, he served seven years at AstraZeneca in various senior roles, including Sales and Marketing Vice President Europe, Global Vice President Respiratory, General Manager of the Balkans and Vice President Primary Care in Italy. Prior to that, he served for two years as BU Director Metabolic & Cardiovascular at GlaxoSmithKline and five years in various sales and marketing roles at Eli Lilly and Company in both Italy and the United States. Mr. Nazzi received his BA degree in economics from the University of Udine, and his master’s degree in management studies from SDA Bocconi.
As the Executive Vice President - International Markets Commercial of Teva- Pharmaceutical Industries, the total compensation of Gianfranco Nazzi at Teva- Pharmaceutical Industries is $3,449,170. There are 5 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
Gianfranco Nazzi is 51, he's been the Executive Vice President - International Markets Commercial of Teva- Pharmaceutical Industries since 2017. There are 20 older and 7 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
Gianfranco's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL STREET, PETACH TIKVA, L3, 4951033.
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks, and Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include: